Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 7, pp. 1042-1055
Open Access | Times Cited: 165

Showing 1-25 of 165 citing articles:

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 685-699
Open Access | Times Cited: 2326
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 11, pp. 1788-1800
Closed Access | Times Cited: 357
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, et al.
Arthritis Research & Therapy (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 280
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Mahesh V. Madhavan, Behnood Bikdeli, Aakriti Gupta, et al.
Thrombosis and Haemostasis (2020) Vol. 120, Iss. 07, pp. 1004-1024
Open Access | Times Cited: 244
Tofacitinib: A Review in Rheumatoid Arthritis
Sohita Dhillon
Drugs (2017) Vol. 77, Iss. 18, pp. 1987-2001
Closed Access | Times Cited: 241
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 760-770
Open Access | Times Cited: 228
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 226
C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Janet Pope, Ernest Choy
Seminars in Arthritis and Rheumatism (2020) Vol. 51, Iss. 1, pp. 219-229
Open Access | Times Cited: 207
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 11, pp. 1400-1413
Open Access | Times Cited: 186
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout
Romy Hansildaar, Daisy Vedder, Milad Baniaamam, et al.
The Lancet Rheumatology (2020) Vol. 3, Iss. 1, pp. e58-e70
Open Access | Times Cited: 184
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
James T. England, Alym Abdulla, Catherine M. Biggs, et al.
Blood Reviews (2020) Vol. 45, pp. 100707-100707
Open Access | Times Cited: 180
<p>JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data</p>
Robert Harrington, Shamma Ahmad Al Nokhatha, Richard Conway
Journal of Inflammation Research (2020) Vol. Volume 13, pp. 519-531
Open Access | Times Cited: 175
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19
Xiuhong Zhang, Yan Zhang, Weizhen Qiao, et al.
International Immunopharmacology (2020) Vol. 86, pp. 106749-106749
Open Access | Times Cited: 167
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
William J. Sandborn, Julián Panés, Bruce E. Sands, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 50, Iss. 10, pp. 1068-1076
Open Access | Times Cited: 151
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
RMD Open (2020) Vol. 6, Iss. 3, pp. e001395-e001395
Open Access | Times Cited: 144
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 335-343
Open Access | Times Cited: 116
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms
Chiara Baldini, Francesca Romana Moriconi, Sara Galimberti, et al.
European Heart Journal (2021) Vol. 42, Iss. 42, pp. 4389-4400
Open Access | Times Cited: 111
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 81
Impact of COVID-19 on Cardiovascular Disease
Ivan Vosko, Andreas Zirlik, Heiko Bugger
Viruses (2023) Vol. 15, Iss. 2, pp. 508-508
Open Access | Times Cited: 65
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 54
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Zoltán Szekanecz, Maya H Buch, Christina Charles‐Schoeman, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 101-115
Closed Access | Times Cited: 51
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Ian C. Scott, Samantha Hider, David L. Scott
Drug Safety (2018) Vol. 41, Iss. 7, pp. 645-653
Closed Access | Times Cited: 138
Page 1 - Next Page

Scroll to top